At Elpis, we are developing therapeutics that target and activate the immune response to eradicate tumors and deliver improved outcomes for patients with difficult-to-treat and resistant cancers.
- Elpis Biopharmaceuticals Showcases Preclinical Data from its Transformative Multi-functional Immuno-Oncology Programs at 2022 AACR Annual Meeting
- Elpis Appoints Leading Immuno-Oncology Expert Dr. Vincenzo Bronte to its Scientific Advisory Board
- Elpis Biopharmaceuticals Strengthens Scientific Advisory Board
- Elpis Biopharmaceuticals Debuts with Series A Funding and Establishment of Scientific Advisory Board